BiologybioRxiv
Ranked by formulaVerdict: NotablePopulation-scale drug target and variant prioritization with Varformer
Human genetic variation is a powerful driver of therapeutic target prioritization, yet current models struggle to aggregate variable numbers of variants per gene and are bottlenecked by the scarcity of validated targets.
Key numbers
- 20% and DrugnomeAI by 23%
- 57% of pairs
Caveats
- Preprint; not yet peer reviewed.
VerdictWorth a reader's time today.
Abstract
Human genetic variation is a powerful driver of therapeutic target prioritization, yet current models struggle to aggregate variable numbers of variants per gene and are bottlenecked by the scarcity of validated targets. We present Varformer, a multimodal transformer that uses cross-modal attention to integrate contextual representations of missense variants with gene-level features. Trained via positive-unlabeled learning on clinically validated targets across four genetic ancestry groups, Varformer achieves a precision@20 of 0.95, 0.86, and 0.48 across three benchmarks of increasing difficulty. It surpasses a logistic regression ablation by 20% and DrugnomeAI by 23% on the hardest benchmark. Cross-population rank normalization isolates targets with consistent genetic support across ancestry groups. The variant encoder also scores individual variants. Across 1,164 carrier-variant pairs in Genes & Health, Varformer ranked the known pathogenic variant in the carrier's top 20 in 57% of pairs. Varformer is available as an open-source framework for unified target and variant prioritization.
The editor's rubric
- Leverage4 / 5
- A general-purpose tool used across several fields (Adam, ResNet, LoRA, next-generation sequencing).
- Magnitude3 / 5
- Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.
- Evidence3 / 5
- Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data.
- Novelty2 / 5
- A new combination of known ideas.
- Trajectory3 / 5
- A clear path to scale.
- Stakes3 / 5
- Meaningful benefit to many people within a few years.
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we propose); breadth (many tasks); gains (outperforms); verification (multiple benchmarks, ablations, experimental validation); scale (scalable); stakes (genetic disease, prevention or cure).
How the score was computed
Desks place stronger verdicts first, then use this score to order work within the same verdict.
- Merit
- 6.1 / 10
- Adjusted merit
- 5.0 / 10
- Attention
- 0%
- Freshness
- 88%